ArticleJournal of cellular and molecular medicine2021

Bisphosphonate-enoxacin inhibit osteoclast formation and function by abrogating RANKL-induced JNK signalling pathways during osteoporosis treatment.

Qiang Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.